Dyax Corp. receives FDA breakthrough therapy designation for DX-2930
Dyax announced the FDA granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary angioedema. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of HAE attacks. July 07, 2015